Abstracts Accepted for Publication 2019
DOI: 10.1136/annrheumdis-2019-eular.3790
|View full text |Cite
|
Sign up to set email alerts
|

Ab1211 a Retrospective Analysis of Laboratory Abnormalities Found During Methotrexate Monitoring and the Cost Implications

Abstract: BackgroundMethotrexate (MTX) remains the first line treatment in majority of cases of inflammatory arthritis. The current British Society of Rheumatology (BSR) Guidelines suggest checking Full blood Count (FBC), ALT/AST, Albumin, Creatinine at 0,2,4,6,10,14, 18 weeks and then 12 weekly. Despite this close monitoring recommendation, MTX is generally considered a safe drug by Rheumatologists and its use has grown significantly over last two decades.ObjectivesTo evaluate the incidence of liver, renal and haematol… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles